Dr Paolo Caimi speaks to ecancer about a study presented at ASH 2024 which evaluated glofitamab in combination with rituximab plus ifosfamide, carboplatin and etoposide in relapsed refractory (RR) diffuse large B-cell lymphoma patients eligible for stem cell transplant or chimeric antigen receptor T-cell therapy.

He reports that 42 patients were evaluated with an overall response rate of 83% and a complete response rate of 66.7%.

Dr Caimi also details the safety profiles which were manageable with a low discontinuation rate.